You are here:  Home page > Company Profile


Zhejiang Medicine Co., Ltd.
168 Mid Zhiyuan Avenue,Binhai New Area,Shaoxing City,Zhejiang Province,312366, P.R.China

Tel: +86-575-85211979

Company Profile

Zhejiang Medicine Co., Ltd. (hereinafter referred to as “ZMC”) is a large pharmaceutical stock-shared corporation established in May 1997. After being approved by the CSRC, ZMC issued 58 million public A shares in August 1999 and was listed via Shanghai Stock Exchange in October of the same year. With a registered capital of RMB 965 million, the current corporate annual sales income is close to 5 billion yuan and its total assets, up to 9 billion yuan.

ZMC currently owns six subsidiaries (Xinchang Pharmaceutical Factory, Vitamin Factory, Changhai Biological Company, Zhejiang Health Creation Biotechnology Co., Ltd., Zhejiang Health Creation Pharmaceutical Co., Ltd. and Shanghai Vital Health Management Co., Ltd.) and two R&D units (Research Institute of Pharmaceutical Industry and Shanghai Health Creation Biological Drug Research and Development Center). It is rated as the “National High-Tech Enterprise” and “National Innovative Enterprise” having National Enterprise Technology Center and National Post-doctor Scientific Research Station at its core.

ZMC specializes in large-scale production of fat-soluble vitamins, quasi-vitamins, quinolone antibiotics, anti-drug-resistant antibiotics and other products. The corporation has formulated a range of dominant products through in depth and extensive studies. In addition to fat soluble vitamins which include VE, natural VE, VA, Biotin, Coenzyme Q10, carotenoids likeβ-carotene, Canthaxanthin, Astaxanthin, Lycopene, Zeaxanthin and Lutein, ZMC also produces Vancomycin HCl, Teicoplanin, Levofloxacin, Miglitol, in the form of APIs and FDF. Manufacturing in ZMC’s domestically model FDF Industrial Park is the 8 other dosage forms: large-volume injections, small-volume injections, freeze dried powder injections, tablets, hard capsules, soft capsules, pills and oral solutions.

Taking globalization as its standpoint, the development strategy of ZMC encompasses innovative entrepreneurship, competitive development, scientific technology advancement and talent implementation. By focusing on developing products, highlighting structure readjustment, re-organizing and integrating various resources, and strengthening its technological innovation in methods and products, ZMC is to build a consummate market network and to build a pristine image for its branded products on top of promoting its corporate culture and competitiveness in its core business. At presence, ZMC is recognized as a large global influential pharmaceutical corporation with advanced technology, strong capital and technical strengths.

Honors & Awards

Coartem Development, Internationalization and Industrialization project won the first prize of Yunnan Provincial Science and Technology Progress Award in 2007

"Vancomycin key technology and industrialization" project won the second prize of National Science and Technology Progress Award in 2007

"the d-Biotin asymmetric synthesis production technology" project won the second prize of National Technology Invention Award in 2005

"Natural d-α-tocopherol technology innovation" project won the second prize of National Science and Technology Progress Award in 2001

More R&D releases